Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-18T20:41:44.588Z Has data issue: false hasContentIssue false
  • English
  • Français

Beneficial effect of an oral analog of prostacyclin on pulmonary hypertension secondary to congenital heart disease

Published online by Cambridge University Press:  19 August 2008

Fukiko Ichida ,
Kei-ichiro Uese ,
Shin-ichi Tsubata ,
Ikuo Hashimoto ,
Yuji Hamamichi ,
Kazuaki Fukahara ,
Arata Murakami  and
Toshio Miyawaki
Fukiko Ichida*
Affiliation:
Department Pediatrics of and the First Division of Surgery, Toyama Medical and Pharmaceutical University, Toyama, Japan
Kei-ichiro Uese
Affiliation:
Department Pediatrics of and the First Division of Surgery, Toyama Medical and Pharmaceutical University, Toyama, Japan
Shin-ichi Tsubata
Affiliation:
Department Pediatrics of and the First Division of Surgery, Toyama Medical and Pharmaceutical University, Toyama, Japan
Ikuo Hashimoto
Affiliation:
Department Pediatrics of and the First Division of Surgery, Toyama Medical and Pharmaceutical University, Toyama, Japan
Yuji Hamamichi
Affiliation:
Department Pediatrics of and the First Division of Surgery, Toyama Medical and Pharmaceutical University, Toyama, Japan
Kazuaki Fukahara
Affiliation:
Department Pediatrics of and the First Division of Surgery, Toyama Medical and Pharmaceutical University, Toyama, Japan
Arata Murakami
Affiliation:
Department Pediatrics of and the First Division of Surgery, Toyama Medical and Pharmaceutical University, Toyama, Japan
Toshio Miyawaki
Affiliation:
Department Pediatrics of and the First Division of Surgery, Toyama Medical and Pharmaceutical University, Toyama, Japan
*
Fukiko Ichida, MD, Department of Pediatrics, Toyama Medical and Pharmaceutical University, Sugitani, Toyama, 930-01Japan Tel: 81-764-34-2281, Fax 81-764-34-5029
Get access Rights & Permissions [Opens in a new window]

Abstract

To determine whether a newly synthesized oral analog of prostacyclin, called beraprost sodium, could cause pulmonary vasodilation, we studied its hemodynamic effect on pulmonary hypertension of children, comparing it to other vasodilatory agents, such as nitric oxide and tolazoline. We studied 20 children (mean age 24 months) having pulmonary hypertension secondary to congenital heart disease. A single oral dose of beraprost sodium resulted in an appreciable reduction of pulmonary vascular resistance (mean 34%), which was comparable to that induced by inhalation of nitric oxide and intravenous delivery of tolazoline (mean 41% and 31%, respectively). The results suggest that beraprost sodium may serve as a novel and safe vasodilator for the screening of pulmonary vasoreactivity, as well as the treatment of pulmonary hypertension in children.

Keywords

Pulmonary hypertensionoral prostacyclin analognitric oxidecongenital heart disease
Type
Original Articles
Information
Cardiology in the Young , Volume 8 , Issue 2 , April 1998 , pp. 205 - 210
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bush, A, Busst, CM, Hawoth, SG, Hislop, AA, Knight, WB, Corrin, B, Shinebourne, EA.Correlation of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease. Br Heart J 1988; 59: 480–485.Google Scholar
2.Bush, A, Busst, C, Booth, K, Knight, WB, Shinebourne, EA.Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease? Circulation 1986; 74: 135–144.Google Scholar
3.Schranz, D, Zepp, F, Iversen, S, Wippermann, C, Huth, R, Zimmer, B, Jungst, BK, Oelert, H.Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery. Crit Care Med 1992; 20: 1243–1249.Google Scholar
4.Roberts, JD, Lang, F, Bigatello, LM, Vlahakes, GJ, Zapol, WM.Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87: 447–453.CrossRefGoogle ScholarPubMed
5.Goldman, AP, Delius, RE, Deanfield, JE, Macrae, DJ.Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann Thorac Surg 1995; 60: 300–306.CrossRefGoogle ScholarPubMed
6.Jones, OD, Shore, DF, Rigby, ML, Leijala, M, Scallan, J, Shinebourne, EA, Lincoln, JC.The use of tolazoline hydrochloride as a pulmonary vasodilator in potentially fatal episodes of pulmonary vasoconstriction after cardiac surgery in children. Circulation 1981; 64(Suppl 11): 134–139.Google ScholarPubMed
7.Toda, N.Beraprost sodium. Cardiovascular Drug Reviews 1988; 6: 222–238.Google Scholar
8.Takeo, S.Pharmacodynamics and clinical studies with beraprost sodium, a drug for peripheral vascular disease. Cardiovascular Drug Reviews 1992; 10: 392–403.Google Scholar
9.Saji, T, Ozawa, Y, Aoki, Y, Ishikita, T, Matsuura, H, Matsuo, N.Short-term hemodynamic effect of a new oral PGI2 analog, Beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78: 244–247.CrossRefGoogle ScholarPubMed
10.LaFarge, CG, Miettinen, OS.The estimation of oxygen consumption. Cardiovasc Res 1970; 4: 23–30.Google Scholar
11.Katz, RW, Pollack, MM, Weibley, RE.Pulmonary artery catheterization in pediatric intensive care. Adv Pediatr 1984; 30: 169–190.CrossRefGoogle Scholar
12.Day, RW, Lynch, JM, Shaddy, RE, Orsmond, GS.Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. Am J Cardiol 1996; 75: 196–198.CrossRefGoogle Scholar
13.Graham, DR, Keldermans, MM, Klemm, LW, Semenza, NJ, Shafer, ML.Infectious complications among patients receiving home intravenous therapy, with peripheral, central, or peripherally placed central venous catheters. Am J Med 1991; 91: 955–100S.Google Scholar
14.Santak, B, Schreiber, M, Kuen, F, Lang, D, Radermacher, P.Prostacyclin aerosol in an infant with pulmonary hypertension EurJ Pediatr 1995; 154: 233–235.CrossRefGoogle Scholar
15.Celermajer, DS, Cullen, S,Deanfield, JE.Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993; 87: 440–446.CrossRefGoogle ScholarPubMed